Differential action of ErbB kinase inhibitors on receptor oligomerization

被引：0
|
作者：
Sanchez-Martin, M. [1 ]
Pandiella, A. [1 ]
机构：
[1] Ctr Invest Canc, Lab 15, Salamanca, Spain
来源：
EJC SUPPLEMENTS | 2010年 / 8卷 / 07期
关键词：
D O I：
10.1016/S1359-6349(10)72044-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：107 / 108
页数：2
相关论文
共 50 条
  • [41] Neutral 5-substituted 4-indazolylaminoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase
    Barlaam, Bernard
    Acton, David G.
    Ballard, Peter
    Bradbury, Robert H.
    Cross, Darren
    Ducray, Richard
    Germain, Herve
    Hudson, Kevin
    Klinowska, Teresa
    Magnien, Francoise
    Ogilvie, Donald J.
    Olivier, Annie
    Ross, Helen S.
    Smith, Robin
    Trigwell, Cath B.
    Vautier, Michel
    Wright, Lindsay
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (06) : 1799 - 1803
  • [42] Neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase
    Ballard, Peter
    Barlaam, Bernard C.
    Bradbury, Robert H.
    Dishington, Allan
    Hennequin, Laurent F. A.
    Hickinson, D. Mark
    Hollingsworth, Ian M.
    Kettle, Jason G.
    Klinowska, Teresa
    Ogilvie, Donald J.
    Pearson, Stuart E.
    Scott, James S.
    Suleman, Abid
    Whittaker, Robin
    Williams, Emma J.
    Wood, Robin
    Wright, Lindsay
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (22) : 6326 - 6329
  • [43] Receptor tyrosine kinase inhibitors in thyroid cancer
    Castellone, Maria Domenica
    Carlomagno, Francesca
    Salvatore, Giuliana
    Santoro, Massimo
    [J]. BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2008, 22 (06) : 1023 - 1038
  • [44] EGF-receptor protein kinase inhibitors
    Terrett, N
    [J]. DRUG DISCOVERY TODAY, 1996, 1 (10) : 448 - 448
  • [45] INHIBITORS OF THE INSULIN-RECEPTOR TYROSINE KINASE
    SRINIVAS, PR
    GRUNBERGER, G
    [J]. PHARMACOLOGY & THERAPEUTICS, 1994, 64 (01) : 23 - 35
  • [46] PDGF receptor kinase inhibitors for the treatment of restenosis
    Levitzki, A
    [J]. CARDIOVASCULAR RESEARCH, 2005, 65 (03) : 581 - 586
  • [47] Tumor endothelial cells express epidermal growth factor receptor (EGFR) but not ErbB3 and are responsive to EGF and to EGFR kinase inhibitors
    Amin, DN
    Hida, K
    Bielenberg, DR
    Klagsbrun, M
    [J]. CANCER RESEARCH, 2006, 66 (04) : 2173 - 2180
  • [48] Tropomyosin receptor kinase inhibitors in the management of sarcomas
    Wilding, Christopher P.
    Loong, Herbert H.
    Huang, Paul H.
    Jones, Robin L.
    [J]. CURRENT OPINION IN ONCOLOGY, 2020, 32 (04) : 307 - 313
  • [49] EFFECTS OF RECEPTOR TYROSINE KINASE INHIBITORS ON MENINGIOMAS
    Li, Li
    Daou, Marie-Claire
    Mihaliak, Alicia
    Moser, Richard
    Smith, Thomas
    Ross, Alonzo H.
    [J]. NEURO-ONCOLOGY, 2009, 11 (05) : 638 - 638
  • [50] Biomarker profiling and combination studies of receptor tyrosine kinase inhibitors of EGFR, ERBB2, IGFR-1, FGFR and PDGFR
    O'Day, Christine L.
    Ovechkina, Yulia
    Marcoe, Karen
    Keyser, Robert
    Chesnut-Speelman, Jessica
    Hnilo, James
    [J]. CANCER RESEARCH, 2011, 71
12345